Asymptomatic Lesions of the Pancreas: An Overview

Raffaele Pezzilli, Pancreas Unit, Department of Digestive Diseases and Internal Medicine, Sant’Orsola-Malpighi Hospital, Via Massarenti, 9, 40138 Bologna, Italy
Correspondence to: Raffaele Pezzilli, Pancreas Unit, Department of Digestive Diseases and Internal Medicine, Sant’Orsola-Malpighi Hospital, Via Massarenti, 9, 40138 Bologna, Italy
Email: raffaele.pezzilli@aosp.bo.it
Telephone:+39-051-636-4148 Fax: +39-051-636-4148
Received: April 27, 2014 Revised: May 25, 2014 Accepted: May 28, 2014
Published online: September 21, 2014

ABSTRACT

The issue of pancreatic incidentaloma is relevant in clinical practice, and the correct management of these asymptomatic lesions found incidentally at imaging techniques requires prospective studies with adequate follow-ups. The current literature on this issue was reviewed and incidentalomas, both solid and cystic, are frequently diagnosed at an advanced age and the percentage of males ranged from 14.3 to 80.7%. The percentage of incidentalomas varies from 6% to 23% of the pancreatic resections performed for any cause. The prevalence of cystic incidentalomas diagnosed with imaging techniques varies from 1.2 to 2.6%. Further injury can be identified on the basis of biochemical or endoscopic examinations. Incidentalomas are found more frequently in examinations carried out for genito-urinary symptoms, chest pain or screening tests for cancer surveillance. Up to 50% of these lesions are solid and the vast majority are malignant or precancerous. Biopsy and analysis of the CEA and amylase in the cystic fluid obtained especially with an endoscopic ultrasonography is of particular importance. Given the imperfect diagnostic information available, it is necessary to evaluate the risk and benefit of a pancreatic resection when deemed appropriate because pancreatic resection involves high morbidity, and a surgical approach should be avoided for a benign condition. Solid incidentalomas generally seem to have a better prognosis than symptomatic lesions.

Key words: Cystic lesions; Solid lesions; Pancreatic neoplasms; Magnetic resonance imaging; Computer tomography; Endoscopic ultrasonography

Pezzilli R. Asymptomatic Lesions of the Pancreas: An Overview. Journal of Gastroenterology and Hepatology Research 2014; 3(9): 1216-1219 Available from: URL: http://www.ghrnet.org/index.php/joghr/article/view/851

INTRODUCTION

The definition of incidentaloma is “a chance discovery in a patient which may warrant further investigation”\(^{[1]}\); the definition of pancreatic incidentaloma was introduced in 2010 and defines the asymptomatic lesions of the pancreas as “a solid or cystic lesion detected incidentally by computed tomography, magnetic resonance imaging or other imaging techniques carried out for other purposes and which never gave signs by which they could be predicted”\(^{[2]}\). The term previously used for incidentaloma was "anticipated lesion", but these lesions discovered by chance cannot be anticipated clinically or radiologically\(^{[3]}\); thus, the correct term is incidentaloma. From the point of view of forensics, also arises the problem of why it had not been not suspected on the basis of the information at hand also arises\(^{[4]}\). From the point of view of health economics, there is the need to develop medical strategies to optimize results, minimize costs and ensure the proper application of clinical decision-making\(^{[5]}\).

LITERATURE REVIEW

The current literature on this issue was reviewed and very few papers dealing this topic were found. In tables 1 and 2. are summarized the characteristics of the studies selected as related to solid and cystic lesions diagnosed incidentally, and the type of study (all retrospective), the number of patients enrolled, age at diagnosis, the reasons for which they had undergone the radiological investigation as a result of which the incidentaloma was diagnosed, the final diagnosis of incidentaloma, the type of surgery performed and, finally, the percentage of non-operated on patients have been reported.

© 2014 ACT. All rights reserved.
Incidentalomas, both solid and cystic, are frequently diagnosed at an advanced age [6,12] and the percentage of males ranged from 14.3 to 80.7% [10-12]. The percentage of incidentalomas varies from 6% to 23% of the pancreatic resections performed for any cause [6,7,11].

This is due in large part to a growing number of radiologic studies performed for other reasons; the prevalence of cystic incidentalomas diagnosed with imaging techniques varies from 1.2 to 2.6% [8,15]. Further injury can be identified on the basis of biochemical (alterations of serum liver and/or pancreatic enzymes) or endoscopic examinations (abnormalities of the duodenum or papilla of Vater) [6,7,10]. Incidentalomas are found more frequently in examinations (alterations of serum liver and/or pancreatic enzymes) or endoscopic examinations (abnormalities of the duodenum or papilla of Vater) [6,7]. The percentage of incidentalomas varies from 6% to 23% of the pancreatic resections performed for any cause [6,7,16].

It should be noted that not all lesions have a malignant potential; thus, they require a careful preoperative evaluation. In this regard it should be noted that the biopsy and analysis of the CEA and amylase in the cystic fluid obtained, especially with an endoscopic ultrasonography is of particular importance [9,14]. Given the imperfect diagnostic information available, it is necessary to evaluate the risk and benefit of a pancreatic resection when deemed appropriate because pancreatic resection involves high morbidity, and a surgical approach should be avoided for a benign condition. Solid incidentalomas generally seem to have a better prognosis than symptomatic lesions [3-5].

### INCIDENTALOMAS IN FAMILIAL PANCREATIC CANCER

Similarly to other cancers, such as colon cancer, pancreatic adenocarcinoma may be present in the same family [17]. It should be pointed out that subjects from families with a history of pancreatic cancer have an inherited predisposition of developing the disease, and subjects having familial pancreatic cancer may have at least two first-degree relatives with this disease, probably demonstrating autosomal dominant transmission [19]. A computer-based risk assessment tool has been developed and it has been shown to provide an accurate risk assessment for relatives with familial pancreatic cancer [20]. In addition, several studies have been carried out on patients with familial pancreatic cancer [20-24] and the most frequent pre-neoplastic lesions incidentally found are intraductal papillary mucinous neoplasms.

## COST-EFFECTIVENESS OF FOLLOW-UP

Information on cost-effectiveness in the case of lesions found incidentally is largely lacking and the information comes mainly from studies enrolling patients with cystic lesions. It has been reported that, even in patients operated on for lesions greater than 3 cm, the survival rate is good; the only contraindication in patients having
cystic lesions >3 cm is when the patients are >85 years of age and there is the presence of comorbidities.[27] Endoscopic ultrasonography in selected cases adds an additional benefit onto the cost-effectiveness of a follow-up for these patients.[28] At present, in the case of solid pancreatic lesions detected incidentally, only a consensus of experts may assess the cost-effectiveness of the work-up and this suggestion is a reasonable intermediate goal for which additional data is awaited in the near future.[27]

In conclusion, in order to initiate chemotherapy, preoperative histologic characterization in the presence of a solid pancreatic incidentaloma is required, especially when distant metastatic lesions are present. Histology is also necessary when clinical and radiologic signs are compatible with benign lesions, such as focal chronic pancreatitis or autoimmune pancreatitis.[31] In the case of a cystic incidentaloma <2 cm in diameter, a radiologic follow-up carried out yearly is recommended; in the presence of cystic lesions between 2 and 3 cm in diameter, a follow-up twice a year is suggested; finally, in the case of the radiographic appearance of worrisome features, such as mural nodules and thickening septa, and a cystic lesion of greater than 3 cm, if the patient does not have a high operative risk, surgery seems to be a good approach.[26,29]

Finally, screening relatives from families in which pancreatic cancer is familial has a significant diagnostic yield, even if the major part of the pancreatic lesions found are pre-neoplastic; this is particularly true in relatives >65 years of age, confirming prior studies which show that magnetic resonance cholangiopancreatography as an initial screening modality is safe and effective.[2,29].

CONCLUSION
The issue of pancreatic incidentaloma is relevant in clinical practice, and the correct management of these asymptomatic lesions found incidentally at imaging techniques requires prospective studies with adequate follow-ups also regarding the economic evaluation of different diagnostic and treatment strategies.

CONFLICT OF INTERESTS
There are no conflicts of interest with regard to the present study.

REFERENCES

1. http://medical-dictionary.thefreedictionary.com/Incidental+Finding
2. Berland LL, Silverman SG, Gore RM, Mayo-Smith WW, Megibow AJ, Yee J, Brink BA, Baker ME, Federle MP, Foley WD, Francis IR, Herts BR, Israel GM, Kirsinsky G, Platt JF, Shuman WP, Taylor AJ. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol 2010; 7: 754-
Pezzilli R. Asymptomatic lesions of the pancreas

1 Parker LS. The future of incidental findings: should they be viewed as benefits? J Law Med Ethics 2008; 36: 341-345
2 Fletcher RH, Pignone M. Extracolonic findings with computed tomographic colonography: asset or liability? Arch Intern Med 2008; 168: 685-686
3 Elstein AS. On the origins and development of evidence-based medicine and medical decision making. Inflamm Res 2004; 53 (Suppl 2): S184-S189
4 Sachs T, Pratt WB, Callery MP, Vollmer CM Jr. The incidental asymptomatic pancreatic lesion: nuisance or threat? J Gastrointest Surg 2009; 13: 405-415
5 Winter JM, Cameron JL, Lillemoe KD, Campbell KA, Chang D, RiaI TL, Coleman J, Sauter PK, Canto M, Hruban RH, Schulick RD, Choi MA, Yeo CJ. Periampullary and pancreatic incidentaloma: a single institution’s experience with an increasingly common diagnosis. Ann Surg 2006; 243: 673-680
6 Lahat G, Ben Haim M, Nachmany I, Sever R, Blachar A, Nakache R, Klausner JM. Pancreatic incidentalomas: high rate of potentially malignant tumors. J Am Coll Surg 2009; 209: 313-319
7 Lahav M, Maoor Y, Avidan B, Novis B, Bar-Meir S. Nonsurgical management of asymptomatic incidental pancreatic cysts. Clin Gastroenterol Hepatol 2007; 5: 813-817
8 Goodman M, Willmann JK, Jeffrey RB. Incidentally discovered solid pancreatic masses: imaging and clinical observations. Abdom Imaging 2012; 37: 91-97
9 Fernández-del Castillo C, Targarona J, Thayer SP, Rattner DW, Brugge WR, Warshaw AL. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003; 138: 427-433
10 Pausawadi N, Heidt D, Kwon R, Simeone D, Scheiman J. Long-term follow-up of patients with incidentally discovered pancreatic cystic neoplasms evaluated by endoscopic ultrasound. Surgery 2010; 147: 13-20
11 Spinelli KS, Fromwiller TE, Daniel RA, Kiely JM, Nakeeb A, Komorowski RA, Wilson SD, Pitt HA. Cystic pancreatic neoplasms: observe or operate. Ann Surg 2004; 239: 651-657
12 Laffan TA, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S, Johnson PT, Fishman EK, Hruban RH. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol 2008; 191: 802-807
13 Raluyak SJ, Brentnall TA. Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology 2001; 1: 477-485
14 Greenhalf W, Grocock C, Harcus M, Neoptolemos J. Screening of high-risk families for pancreatic cancer. Pancreatology 2009; 9: 215-222
15 Wang W, Chen S, Brune KA, Hruban RH, Parmigiani G, Klein AP. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007; 25: 1417-1422
16 Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, Fishman EK, Brune K, Axilbund J, Griffin C. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006; 4: 766-781
17 Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, Ali SZ, Jagannath S, Petersen GM, Fishman EK. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2: 606-621
18 Kimmey MB, Bronner MP, Byrd DR, Brentnall TA. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 2002; 56: S82-S86
19 Carlson C, Greenhalf W, Brentnall TA. Screening of hereditary pancreatic cancer families. In: Berger HG, Bucher M, Kozarek R, Lerch M, Neoptolemos J, editors. The Pancreas: An Integrated Textbook of Basic Science, Medicine and Surgery. 2nd ed. Oxford, UK: Wiley-Blackwell Publishing; 2008: pp. 636-642
20 Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, Slater EP, Everhagen JT, Gross TM, Rothmund M. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009; 58: 1410-1418
21 Krop I, Luna MA, El-Naggar AK, Amundson AS, Beckwith JA, Behrens C, Birkett DJ, Blum RK, Booser DJ, Coit DG, et al. A national cooperative group experience in molecular screening for high-risk individuals from families with familial pancreatic cancer. J Clin Oncol 2009; 27: 2015-2021
22 Ludwig E, Olson SH, Bayuga S, Simon J, Schattner MA, Gerdes H, Allen PJ, Jarnagin WR, Kurtz RC. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011; 106: 946-954
23 Weinberg BM, Spiegel BM, Tomlinson JS, Farell JJ. Asymptomatic pancreatic cystic neoplasms: maximizing survival and quality of life using Markov-based clinical nomograms. Gastroenterology 2010; 138: 531-540
24 Das A, Ngampaengpong S, Nagendra S, Chak A. Asymptomatic pancreatic cystic neoplasm: a cost-effectiveness analysis of different strategies of management. Gastrointest Endosc 2009; 70: 690-699
25 Tanaka M, Ferrari DJ, Yeo CJ, Goggins M, Fishman EK, Hruban RH. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol 2008; 191: 802-807
26 Peer reviewers: Shoji Nakamori, Head Director, Chief Surgeon, Osaka National Hospital, Osaka, Japan; Pavel Soucek, PhD, Head, Toxicogenomics Unit, National Institute of Public Health, Srobarova 48, Prague 10, 100 42 Czech Republic.